Loading patent…
AssigneeMacroGenics, Inc.
InventorsScott Koenig, Ronald Wilder, Ezio Bonvini, Leslie Johnson
Estimating the term…
The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-CD3 antibodies.
A method of treating an autoimmune disorder or ameliorating the symptoms thereof in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an anti-CD3 antibody that has at least 50% reduced binding to at least one FcγR than an antibody with a wild type Fc domain, wherein said administration results in minimal toxicity.
A method of treating an autoimmune disorder or ameliorating the symptoms thereof in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an anti-CD3 antibody that has at least 50% reduced binding to at least one FcγR than an antibody with a wild type Fc domain, wherein said administration reduces the symptoms of cytokine release syndrome relative to an equivalent administration of murine OKT3.
(canceled)
(canceled)
17-18. (canceled)
22-23. (canceled)
25-26. (canceled)
(canceled)
(canceled)
(canceled)
35-41. (canceled)
43-49. (canceled)
51-61. (canceled)
63-72. (canceled)
(canceled)
79-80. (canceled)
82-83. (canceled)
Dependencies are inferred from the claim text.